Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report

INTRODUCTION: Although there is a considerable amount of data in the literature on safe discontinuation of first-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, little is known about discontinuation of second-generation tyrosine kinase inhibitor therapy. Most...

Descripción completa

Detalles Bibliográficos
Autores principales: Caocci, Giovanni, Greco, Marianna, La Nasa, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160914/
https://www.ncbi.nlm.nih.gov/pubmed/25194418
http://dx.doi.org/10.1186/1752-1947-8-295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160914/
https://www.ncbi.nlm.nih.gov/pubmed/25194418
http://dx.doi.org/10.1186/1752-1947-8-295

Ejemplares similares